← Leaderboards
Saravut Weroha
Mayo Clinic Rochester
$5,625,190
Attributed
$6,895,201
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $985K · FY2015–25$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,895,201 · 6
By mechanism
R01$4,611,284 · 2
P50$1,107,691 · 2
K12$771,113 · 1
R21$405,113 · 1
Top collaborators
- Fergus Joseph Couch6 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Fergus Joseph Couch$34,303,973
- Sumithra Jay Mandrekar$59,945,709
- Scott H Kaufmann$29,002,745
- Paul Haluska$2,010,168
- Jun Yin$123,141
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryResponseTumorWomanNovel TherapeuticsCell LineGenesFutureClinical TrialsHistologicResistancePatient Derived Xenograft ModelClinically RelevantGenotypeCellsClinicProteinsMalignant NeoplasmsPredictive MarkerNovel Therapeutic InterventionOvarianEngraftmentCollectionMolecular
Grant awards (17)
Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic$771,113
K12 · FY2025 · CA · contact PI
Core D: Animal Models$213,926
P50 · FY2025 · CA · contact PI
The contribution of RAD51C and RAD51D to breast and ovarian cancer$289,844
R01 · FY2024 · CA
Core D: Animal Models$220,809
P50 · FY2024 · CA · contact PI
Core D: Animal Models$231,409
P50 · FY2023 · CA · contact PI
Targeting poly (ADP ribose) polymerase (PARP) in endometrial cancer$182,115
R21 · FY2023 · CA · contact PI
The contribution of RAD51C and RAD51D to breast and ovarian cancer$451,372
R01 · FY2022 · CA
Core D: Animal Models$228,225
P50 · FY2022 · CA · contact PI
Targeting poly (ADP ribose) polymerase (PARP) in endometrial cancer$222,998
R21 · FY2022 · CA · contact PI
The contribution of RAD51C and RAD51D to breast and ovarian cancer$476,517
R01 · FY2021 · CA
Core D: Animal Models$213,322
P50 · FY2021 · CA · contact PI
The contribution of RAD51C and RAD51D to breast and ovarian cancer$311,277
R01 · FY2020 · CA
The contribution of RAD51C and RAD51D to breast and ovarian cancer$499,954
R01 · FY2019 · CA
The contribution of RAD51C and RAD51D to breast and ovarian cancer$511,059
R01 · FY2018 · CA
(PQD5) Avatar-directed Treatment for Ovarian Cancer$714,297
R01 · FY2017 · CA · contact PI
(PQD5) Avatar-directed Treatment for Ovarian Cancer$714,297
R01 · FY2016 · CA · contact PI
(PQD5) Avatar-directed Treatment for Ovarian Cancer$642,667
R01 · FY2015 · CA · contact PI